Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Comments Comments
  •  (1)
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
  • PDF PDF

FDA Approve New NNRTI-Based Fixed-Dose Combination of Rilpivirine/Tenofovir/FTC (Complera) in the U.S.

July/August 2011

On 10 August 2011, U.S. Food and Drug Administration (FDA) approved a fixed-dose combination of rilpivirine/tenofovir/FTC (Complera) with an indication in treatment-naive adults. This is a single-tablet once-daily combination.

Approval was based on bioequivilence to the individual drugs taken separately, together with the phase 3 registrational studies for rilpivirine (ECHO and THRIVE) -- see FDA approve rilpivirine in the U.S..


Links to external websites are current at time of posting but not maintained.

View Full Article


  
  • Email Email
  • Comments Comments
  •  (1)
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
  • PDF PDF

Visit HIV i-Base's website to find out more about their activities, publications and services.
 
See Also
More News & Research on Complera (Rilpivirine/Tenofovir/FTC)

Reader Comments:

Comment by: Jair G.-G. (Monterrey, MX) Fri., Sep. 16, 2011 at 9:46 am EDT
This is very hopeful news.
Reply to this comment


Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Tools
 

Advertisement